{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:09:26Z","timestamp":1793797766440,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["IAA AID-GH-T-15-00002"],"award-info":[{"award-number":["IAA AID-GH-T-15-00002"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013965","name":"Eastern Virginia Medical School","doi-asserted-by":"publisher","award":["AID-OAA-A-14-00010"],"award-info":[{"award-number":["AID-OAA-A-14-00010"]}],"id":[{"id":"10.13039\/100013965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["IAA AID-GH-T-15-00002"],"award-info":[{"award-number":["IAA AID-GH-T-15-00002"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ebiom.2022.104361","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T14:11:49Z","timestamp":1669039909000},"page":"104361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques"],"prefix":"10.1016","volume":"86","author":[{"given":"Charles W.","family":"Dobard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Melissa","family":"Peet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nishiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Holder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuong","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onkar N.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Agrahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriramakamal","family":"Jonnalagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Heneine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith R.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gerardo","family":"Garc\u00eda-Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo F.","family":"Doncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104361_bib1","unstructured":"UNAIDS. UNAIDS data 2021.\u00a02021."},{"issue":"11","key":"10.1016\/j.ebiom.2022.104361_bib2","doi-asserted-by":"crossref","first-page":"e1470","DOI":"10.1016\/S2214-109X(19)30404-8","article-title":"HIV incidence rates in adolescent girls and young women in sub-Saharan Africa","volume":"7","author":"Karim","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ebiom.2022.104361_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104361_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104361_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104361_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10337","key":"10.1016\/j.ebiom.2022.104361_bib7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ebiom.2022.104361_bib8","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.ebiom.2022.104361_bib9","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.ebiom.2022.104361_bib10","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104361_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/pharmaceutics11080374","article-title":"Topical inserts: a versatile delivery form for HIV prevention","volume":"11","author":"Peet","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104361_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/COH.0000000000000598","article-title":"Topical delivery of long-acting antiretrovirals to prevent HIV acquisition","volume":"15","author":"Palanee-Phillips","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104361_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2004.11.034","article-title":"The vagina as a route for systemic drug delivery","volume":"103","author":"Hussain","year":"2005","journal-title":"J\u00a0Control Release"},{"issue":"10","key":"10.1016\/j.ebiom.2022.104361_bib14","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1128\/AAC.01152-15","article-title":"In\u00a0vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate","volume":"59","author":"Callebaut","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104361_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.chom.2011.08.015","article-title":"Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication","volume":"10","author":"Andrei","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"227","key":"10.1016\/j.ebiom.2022.104361_bib16","doi-asserted-by":"crossref","first-page":"227ra35","DOI":"10.1126\/scitranslmed.3007701","article-title":"Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors","volume":"6","author":"Dobard","year":"2014","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104361_bib17","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/jac\/dkab293","article-title":"Pharmacokinetics of vaginally applied integrase inhibitors in macaques","volume":"76","author":"Nishiura","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ebiom.2022.104361_bib18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/JVI.05842-11","article-title":"Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue","volume":"86","author":"Dobard","year":"2012","journal-title":"J\u00a0Virol"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104361_bib19","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1371\/journal.pmed.0050157","article-title":"Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel","volume":"5","author":"Cranage","year":"2008","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.ebiom.2022.104361_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050632","article-title":"Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen","volume":"7","author":"Radzio","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2022.104361_bib21","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1371\/journal.pmed.0050028","article-title":"Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir","volume":"5","author":"Garc\u00eda-Lerma","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.ebiom.2022.104361_bib22","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.jchromb.2009.09.007","article-title":"On-line coupling of anion exchange and ion pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors","volume":"877","author":"Kuklenyik","year":"2009","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104361_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","author":"Ramanathan","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.ebiom.2022.104361_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025974","article-title":"A\u00a0multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel","volume":"6","author":"Schwartz","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2022.104361_bib25","series-title":"Multipurpose prevention technologies (MPTs) for prevention of HIV and pregnancy","first-page":"2021","author":"Andrea","year":"2021"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104361_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pst.326","article-title":"Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion","volume":"8","author":"Hummel","year":"2009","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ebiom.2022.104361_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1128\/AAC.00597-11","article-title":"Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques","volume":"56","author":"Nuttall","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ebiom.2022.104361_bib28","series-title":"A\u00a0phase I study to assess safety, pharmacokinetics and pharmacodynamics of a topical multipurpose prevention insert containing tenofovir alafenamide fumarate and elvitegravir dosed vaginally","author":"Thurman","year":"2021"},{"issue":"10","key":"10.1016\/j.ebiom.2022.104361_bib29","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1128\/AAC.03591-14","article-title":"The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in\u00a0vitro","volume":"58","author":"Kulkarni","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104361_bib30","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/infdis\/jiy301","article-title":"Efficacy of vaginally administered gel containing emtricitabine and tenofovir against repeated rectal simian human immunodeficiency virus exposures in macaques","volume":"218","author":"Dobard","year":"2018","journal-title":"J\u00a0Infect Dis"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104361_bib31","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/infdis\/jiz383","article-title":"Efficacy of oral tenofovir alafenamide\/emtricitabine combination or single-agent tenofovir alafenamide against vaginal simian human immunodeficiency virus infection in macaques","volume":"220","author":"Massud","year":"2019","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104361_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100893","article-title":"Safety and pharmacokinetics of a tenofovir alafenamide fumarate-emtricitabine based oral antiretroviral regimen for prevention of HIV acquisition in women: a randomized controlled trial","volume":"36","author":"Thurman","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104361_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1600-0684.1996.tb00202.x","article-title":"Tracking of dye-labeled lymphocytes in rhesus macaques","volume":"25","author":"Salvato","year":"1996","journal-title":"J\u00a0Med Primatol"},{"key":"10.1016\/j.ebiom.2022.104361_bib34","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1128\/JVI.79.14.9217-9227.2005","article-title":"Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus","volume":"79","author":"Miller","year":"2005","journal-title":"J\u00a0Virol"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104361_bib35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/QAD.0000000000001389","article-title":"Topical tenofovir protects against vaginal simian HIV infection in macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis","volume":"31","author":"Makarova","year":"2017","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104361_bib36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJMoa1410649","article-title":"Tenofovir gel for the prevention of herpes simplex virus type 2 infection","volume":"373","author":"Abdool Karim","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ebiom.2022.104361_bib37","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/infdis\/jiz045","article-title":"Tenofovir gel for prevention of herpes simplex virus type 2 acquisition: findings from the VOICE trial","volume":"219","author":"Abdool Karim","year":"2019","journal-title":"J\u00a0Infect Dis"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:35:07Z","timestamp":1778873707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422005436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"alternative-id":["S2352396422005436"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104361","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104361"}}